Overview

Acthar for Treatment of Post-transplant FSGS

Status:
Withdrawn

Trial end date:
2021-07-31

Target enrollment:

Participant gender:

Summary

This is an open label safety and feasibility trial using Acthar® in addition to center-specific standard therapy including plasma exchange, for treatment of post transplant recurrent FSGS and post transplant recurrent idiopathic membranous nephropathy. Subjects will receive Acthar® 40 units subcutaneously (SC) twice weekly for two weeks then 80 units SC twice weekly for 24 weeks.

Phase:

Phase 4

Details

Lead Sponsor:

University of North Carolina, Chapel Hill

Collaborator:

Mallinckrodt

Treatments:

Adrenocorticotropic Hormone
beta-Endorphin
Melanocyte-Stimulating Hormones